featured
Buparlisib Plus Tamoxifen in Pretreated HR+, HER2− Advanced Breast Cancer Stratified for PIK3CA Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Buparlisib in Combination With Tamoxifen in Pretreated Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Molecularly Stratified for PIK3CA Mutations and Loss of PTEN Expression
Cancer Med 2020 Apr 30;[EPub Ahead of Print], A Welt, M Wiesweg, S Theurer, W Abenhardt, M Groschek, L Müller, J Schröder, M Tewes, M Chiabudini, K Potthoff, A Bankfalvi, N Marschner, M Schuler, F BreitenbücherFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.